InMed Pharmaceuticals's market cap is currently $4.09M. The company's EPS TTM is $-14.279; its P/E ratio is ―; InMed Pharmaceuticals is scheduled to report earnings on February 18, 2025, and the estimated EPS forecast is $―. See an overview of income statement, balance sheet, and cash flow financials.

	Jun 24	Jun 23	Jun 22	Jun 21	Jun 20
Income Statement
Total Revenue	$ 4.60M	$ 4.14M	$ 1.09M	$ 0.00	$ 0.00
Gross Profit	$ 1.10M	$ 1.40M	$ 543.55K	$ -197.03K	$ -183.09K
Operating Income	$ 0.00	$ -8.18B	$ -13.70M	$ -9.92M	-
EBITDA	$ -7.06M	$ -10.83M	$ -17.26M	$ -9.80M	-
Net Income	$ -7.68M	$ -7.95M	$ -18.60M	$ -10.20M	$ -8.94M
Balance Sheet
Cash & Short-Term Investments	$ 6.61M	$ 8.91M	$ 6.22M	$ 7.41M	$ 5.84M
Total Assets	$ 11.82M	$ 14.11M	$ 12.79M	$ 9.78M	$ 7.50M
Total Debt	$ 962.66K	$ 391.71K	$ 793.77K	$ 269.77K	$ 316.28K
Net Debt	$ -5.61M	$ -8.52M	$ -5.38M	$ -7.09M	$ -5.48M
Total Liabilities	$ 2.62M	$ 2.02M	$ 3.71M	$ 2.40M	$ 1.92M
Stockholders' Equity	$ 9.21M	$ 12.09M	$ 9.08M	$ 7.38M	$ 5.58M
Cash Flow
Free Cash Flow	$ -7.00M	$ -7.45M	$ -15.62M	$ -9.79M	-
Operating Cash Flow	$ -6.99M	$ -7.28M	$ -15.58M	$ -9.79M	-
Investing Cash Flow	$ -9.29K	$ -661.80K	$ -673.00K	$ -1.73K	$ 3.62M
Financing Cash Flow	$ 4.65M	$ 10.68M	$ 15.07M	$ 10.85M	-

Currency in USD

InMed Pharmaceuticals Earnings and Revenue History

Income Statement >

InMed Pharmaceuticals Debt to Assets

Balance Sheet >

InMed Pharmaceuticals Cash Flow

Cash Flow >

InMed Pharmaceuticals Forecast EPS vs Actual EPS

Earnings >

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing